OLMA
Neutral signalScored 2026-07-29 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Olema Pharmaceuticals, Inc.
- Nom
- Olema Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $560.9M
- Employés
- 150
- PDG
- Sean Bohen
- Site web
- https://www.olema.com
- Marché
- PBYI
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 25 000 titres (~291 162,50 $ US)
- Insiders
- Harmon Cyrus
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-07-24
- Last synced
-
2026-10-19 22:02:11
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-07-29 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
OLMA is a pre-revenue biotech with severe fundamental distress (score: 15), zero commercial activity, and persistent cash burn, making its strong liquidity (score: 75) a temporary buffer rather than a sign of financial…
The first sentence of the analysis written for OLMA on 2026-07-29 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 9.95 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 9.950 | 10.500 | 12.327 | 12.623 | 32.230 | |
| Quick Ratio | 9.950 | 10.500 | 12.327 | 12.623 | 32.230 | |
| Solvency Ratio | -2.952 | -3.072 | -4.177 | -5.770 | -6.235 | |
| Cash Ratio | 0.932 | 3.340 | 3.170 | 1.432 | 1.531 | |
| Price To Earnings Ratio | -13.369 | -2.650 | -6.556 | -0.935 | -5.229 | |
| Price To Earnings Growth Ratio | 0.891 | -0.945 | 0.358 | -0.020 | -0.025 | |
| Forward Price To Earnings Growth Ratio | 0.891 | -0.945 | 0.358 | -0.020 | -0.025 | |
| Price To Earnings Diluted Ratio | -13.369 | -2.650 | -6.556 | -0.935 | -5.229 | |
| Price To Earnings Diluted Growth Ratio | 0.891 | -0.945 | 0.358 | -0.020 | -0.025 | |
| Price To Book Ratio | 4.545 | 0.837 | 2.500 | 0.496 | 1.300 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -14.826 | -3.277 | -7.582 | -1.189 | -7.078 | |
| Price To Operating Cash Flow Ratio | -14.826 | -3.282 | -7.582 | -1.194 | -7.298 | |
| Debt To Assets Ratio | 0.002 | 0.003 | 0.009 | 0.012 | 0.011 | |
| Debt To Equity Ratio | 0.002 | 0.003 | 0.010 | 0.013 | 0.012 | |
| Debt To Capital Ratio | 0.002 | 0.003 | 0.009 | 0.013 | 0.011 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.115 | 1.103 | 1.091 | 1.092 | 1.040 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.832 | -2.499 | -3.872 | -4.959 | -5.620 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.002 | 1.000 | 1.004 | 1.031 | |
| Debt Service Coverage Ratio | -144.093 | -110.137 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -130.530 | -89.037 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -122.981 | -73.024 | -34.641 | -31.994 | -15.412 | |
| Capital Expenditure Coverage Ratio | 0.000 | -656.296 | 0.000 | -226.074 | -32.184 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -656.296 | 0.000 | -226.074 | -32.184 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -13.139 | -1.584 | -5.907 | -0.736 | -5.067 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 9.950 | ▼-0.550 | ▼-5.576 |
| Quick Ratio | 9.950 | ▼-0.550 | ▼-5.576 |
| Solvency Ratio | -2.952 | ▲0.121 | ▲1.489 |
| Cash Ratio | 0.932 | ▼-2.408 | ▼-1.149 |
| Price To Earnings Ratio | -13.369 | ▼-10.719 | ▼-7.621 |
| Price To Earnings Growth Ratio | 0.891 | ▲1.836 | ▲0.840 |
| Forward Price To Earnings Growth Ratio | 0.891 | ▲1.836 | ▲0.840 |
| Price To Earnings Diluted Ratio | -13.369 | ▼-10.719 | ▼-7.621 |
| Price To Earnings Diluted Growth Ratio | 0.891 | ▲1.836 | ▲0.840 |
| Price To Book Ratio | 4.545 | ▲3.708 | ▲2.609 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -14.826 | ▼-11.549 | ▼-8.035 |
| Price To Operating Cash Flow Ratio | -14.826 | ▼-11.544 | ▼-7.989 |
| Debt To Assets Ratio | 0.002 | ▼-0.001 | ▼-0.005 |
| Debt To Equity Ratio | 0.003 | ▼-0.001 | ▼-0.005 |
| Debt To Capital Ratio | 0.003 | ▼-0.001 | ▼-0.005 |
| Long Term Debt To Capital Ratio | 0.000 | ▲0.000 | ▲0.000 |
| Financial Leverage Ratio | 1.115 | ▲0.012 | ▲0.027 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -2.832 | ▼-0.333 | ▲1.124 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.002 | ▼-0.007 |
| Debt Service Coverage Ratio | -144.093 | ▼-33.956 | ▼-93.247 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -130.530 | ▼-41.494 | ▼-86.617 |
| Operating Cash Flow Coverage Ratio | -122.981 | ▼-49.957 | ▼-67.370 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲656.296 | ▲182.911 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲656.296 | ▲182.911 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -13.139 | ▼-11.556 | ▼-7.853 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $2.18B | $342.5M | $634.8M | $98.0M | $369.9M | |
| Enterprise value | $2.13B | $204.4M | $568.7M | $76.9M | $359.4M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -14.51x | -1.96x | -6.79x | -0.94x | -7.09x | |
| EV / Free cash flow | -14.51x | -1.96x | -6.79x | -0.93x | -6.88x | |
| EV / EBITDA | -13.14x | -1.58x | -5.91x | -0.74x | -5.07x | |
| Net debt / EBITDA | 0.29x | 1.07x | 0.69x | 0.20x | 0.15x | |
| Current ratio | 9.95x | 10.50x | 12.33x | 12.62x | 32.23x | |
| Income quality | 0.90x | 0.81x | 0.87x | 0.78x | 0.71x | |
| Graham net-net | $5 | $7 | $5 | $5 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $463.6M | $396.7M | $244.9M | $192.3M | $281.7M | |
| Invested capital | $464.8M | $399.5M | $248.2M | $196.3M | $286.4M | |
| Return on assets | -30.5% | -28.7% | -34.9% | -48.6% | -24.0% | |
| Operating ROA | -36.3% | -39.1% | -42.6% | -41.8% | -22.4% | |
| Return on tangible assets | -30.5% | -28.8% | -34.9% | -48.6% | -24.0% | |
| Return on equity | -33.9% | -31.7% | -38.1% | -53.0% | -25.0% | |
| Return on invested capital | -37.0% | -34.7% | -41.0% | -53.5% | -24.8% | |
| Return on capital employed | -37.1% | -34.8% | -41.1% | -53.7% | -24.9% | |
| Earnings yield | -7.5% | -37.8% | -15.2% | -106.9% | -19.2% | |
| Free cash flow yield | -6.7% | -30.5% | -13.2% | -84.1% | -14.1% | |
| Capex / Op. cash flow | 0.0% | -0.2% | 0.0% | -0.4% | -3.1% | |
| Capex / Depreciation | 0.0% | 40.5% | 0.0% | 101.7% | 966.3% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+535.1%EV / Sales n/aEV / EBITDA ▼-729.7%EV / Op. cash flow ▼-12.546Earnings yield ▲+0.303
Profitability
Return on equity ▼-0.023Return on assets ▼-0.017Return on invested capital ▼-0.024Return on capital employed ▼-0.023Operating ROA ▲+0.028Income quality ▲+0.097Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.550Net debt / EBITDA ▼-0.779Working capital ▲+66935000.000Invested capital ▲+65338000.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▲+488.0%EV / Sales n/aEV / EBITDA ▼-159.3%EV / Op. cash flow ▼-7.414Earnings yield ▲+0.117
Profitability
Return on equity ▼-0.090Return on assets ▼-0.064Return on invested capital ▼-0.122Return on capital employed ▼-0.122Operating ROA ▼-0.139Income quality ▲+0.190Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-22.280Net debt / EBITDA ▲+0.143Working capital ▲+181984000.000Invested capital ▲+178410000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-16 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
- 2026-10-02 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company''s common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema''s Board of Directors and granted under the Company''s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-15 Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup''s Biopharma Back to School Summit 2026 Transcript
- 2026-09-02 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O''Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O''Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company''s common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company''s common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema''s Board of Directors and granted under the Company''s 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates.
- 2026-08-31 Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
- 2026-08-31 66,163 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Connor Clark & Lunn Investment Management Ltd. Connor Clark and Lunn Investment Management Ltd. bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) during the second quarter, according to its most recent filing with the SEC. The firm bought 66,163 shares of the company''s stock, valued at approximately $828,000. Connor Clark and Lunn Investment Management Ltd. owned about 0.08%
- 2026-08-11 Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.
- 2026-08-04 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company''s common stock, effective as of August 3, 2026. These awards were approved by the Compensation Committee of Olema''s Board of Directors and granted under the Company''s 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).